Pharming Group N.V. (PHAR) Stock: Price, Forecast & Analyst Target
Pharming Group N.V. (PHAR) — MoonshotScore 69/100 (Strong band), calculated Nov 18, 2026. Price $11.54 (-5.10%), as of the Nov 20, 2026 trading session; market cap $817M.
Educational signal · not a buy or sell recommendation · How to read this
Pharming Group N.V. · PHAR · NASDAQ
Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for the treatment of rare diseases. The company's lead product, Ruconest, addresses acute hereditary angioedema.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Pharming Group (PHAR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, but stalling growth. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Fading; Momentum: Rising.
- EPS beat 1 of the last 4 reports
- Altman Z 3.15 · Piotroski F 5
- ROE 8.7% · ROA 6.4% · current ratio 3.23
Holding back: soft growth
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 69 | Strong | |
| 69 | Strong | |
| 69 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $11.54 | |
| Change on the day | -5.10% | |
| 52-week range | $9.11 – $21.34 | |
| Market capitalisation | $817M | — |
| Price / earnings (trailing) | 35.00 | |
| Shares traded on the day | 10.5K |
Price & events
Other perspectives
Council score for Pharming Group (PHAR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Pharming Group (PHAR), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pharming Group N.V. (PHAR) is listed on NASDAQ. It employs 407 people and is led by Kenneth Lynard. The market values it at $817M.
What do the latest results show for Pharming Group (PHAR)?
Short answer · as of
Against analyst estimates the company has EPS beat 1 of the last 4 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $97M | $8M | — |
| Q4 FY2025 | $107M | $5M | $0.07 (diluted) |
| Q1 FY2026 | $72M | -$5M | -$0.07 (diluted) |
What are the financial strengths and risks for Pharming Group (PHAR)?
Short answer
The MoonshotScore pillars rate business quality as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 3.15 · Piotroski F 5. Trailing ratios: ROE 8.7% · ROA 6.4% · current ratio 3.23.
What should you watch next at Pharming Group (PHAR)?
Short answer · as of
Current published price targets run low $38.00 · high $38.00 · consensus $38.00 · median $38.00 against a quoted price of $11.54 (as of Nov 20, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Pharming Group compare with its peers?
Short answer
Pharming Group's score ranks tied for 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $60.85 Nov 20, 2026 | $1.76B | 98 5-pillar Nov 18, 2026 | |
| $12.85 Nov 20, 2026 | $1.40B | 97 5-pillar Nov 18, 2026 | |
| $18.41 Nov 20, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $46.63 Nov 20, 2026 | $1.39B | 76 5-pillar Nov 18, 2026 | |
| Pharming Group (PHAR) — this page | $11.54 | $817M | 69 |
| $38.85 Nov 20, 2026 | $1.26B | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 66 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $38.00 – $38.00
- Consensus target
- $38.00
- Median target
- $38.00
Consensus record · Captured .
Measured against a quoted price of $11.54 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 1
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PHAR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PHAR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Pharming Group (PHAR)
These answers are editorial: 1 of these 9 answers is drawn from the PHAR research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PHAR?
PHAR carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PHAR a good stock to buy?
Stock Expert AI does not rate PHAR buy, sell or hold. Pharming Group N.V. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PHAR stock price today?
The last price recorded for Pharming Group N.V. (PHAR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PHAR price target?
The analyst consensus price target for Pharming Group N.V. (PHAR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for PHAR?
The main risks for Pharming Group N.V. include competition from other therapies for hereditary angioedema (HAE), regulatory hurdles and potential delays in drug approval processes, patent expiration and generic competition, and economic downturns and healthcare cost containment measures. Additionally, currency fluctuations can affect the value of the ADR.
What are the key factors to evaluate for PHAR?
Pharming Group N.V. (PHAR) holds a MoonshotScore in the moderate range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. The company's lead product, Ruconest, addresses a critical need in the treatment of acute hereditary angioedema (HAE). Not financial advice.
How frequently does PHAR data refresh on this page?
PHAR's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PHAR's recent stock price performance?
Pharming Group N.V. (PHAR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product Ruconest addresses a critical need in HAE treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHAR overvalued or undervalued right now?
The trailing P/E of Pharming Group N.V. (PHAR) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com